Therapeutic angiogenesis: Translating experimental concepts to medically relevant goals

Vascular Pharmacology

Volumn 45, Issue 5, 2006, Pages 334-339

  Emanueli, Costanza ^a   Madeddu, Paolo ^a,b  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b IRCCS MULTIMEDICA   (Italy)

Author keywords

Angiogenesis; Myocardial and peripheral ischemia; Neovascularization

Indexed keywords

ANGIOGENESIS MODULATOR; ANGIOPOIETIN 1; ANGIOPOIETIN 2; EARLY GROWTH RESPONSE FACTOR 1; FIBROBLAST GROWTH FACTOR 4; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PLACEBO; PLATELET DERIVED GROWTH FACTOR BB; RECOMBINANT FIBROBLAST GROWTH FACTOR; RECOMBINANT FIBROBLAST GROWTH FACTOR 2; RECOMBINANT NERVE GROWTH FACTOR; RECOMBINANT VASCULOTROPIN; SOMATOMEDIN B; TISSUE KALLIKREIN; VASCULOTROPIN 121; VASCULOTROPIN 165; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 1; WNT PROTEIN;

ANGIOGENESIS; ARTERIOVENOUS FISTULA; ARTERY OCCLUSION; ARTICLE; ATHEROSCLEROSIS; CLINICAL TRIAL; DECUBITUS; DIABETIC NEPHROPATHY; DRUG EFFECT; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENVIRONMENTAL FACTOR; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART MUSCLE REVASCULARIZATION; HEREDITY; HUMAN; INTERMITTENT CLAUDICATION; MONOTHERAPY; NEOVASCULARIZATION (PATHOLOGY); NEUROPATHY; NONHUMAN; PERIPHERAL ISCHEMIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOGENESIS INDUCING AGENTS; ANIMALS; EXTREMITIES; GENE THERAPY; HUMANS; ISCHEMIA; MODELS, ANIMAL; MYOCARDIAL ISCHEMIA; NEOVASCULARIZATION, PHYSIOLOGIC; RANDOMIZED CONTROLLED TRIALS; STEM CELL TRANSPLANTATION;

EID: 33751095069     PISSN: 15371891     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vph.2006.08.012     Document Type: Article

References (41)

1. Apfel S.C. Neurotrophic factors in the therapy of diabetic neuropathy. Am. J. Med. 107 (1999) 34S-42S
2. Apfel F.C., et al., rhNGF Clinical Investigator Group. Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy: a randomized controlled trial. JAMA 284 (2000) 2215-2221
3. Azizi M., et al. Arterial and renal consequences of partial genetic deficiency in tissue kallikrein activity in humans. J. Clin. Invest. 115 (2005) 780-787
4. Azizi M., et al. Polymorphism of kallikrein gene and abnormalities of the endothelial function. Med. Sci. 21 (2005) 584-585
5. Bernabei R., et al. Effect of topical application of nerve-growth factor on pressure ulcers. Lancet 354 (1999) 307
6. Chae J.K., et al. Coadministration of angiopoietin-1 and vascular endothelial growth factor enhances collateral vascularization. Arterioscler. Thromb. Vasc. Biol. 20 (2000) 2573-2578
7. Dor Y., et al. Conditional switching of VEGF provides new insights into adult neovascularization and pro-angiogenic therapy. EMBO J. 21 (2002) 1939-1947
8. Doufourq P., et al. FrzA, a secreted frizzled related protein, induced angiogenic response. Circulation 106 (2002) 3097-3103
9. Elson D.A., et al. Induction of hypervascularity without leakage or inflammation in transgenic mice overexpressing hypoxia-inducible factor-1alpha. Genes Dev. 15 (2001) 2520-2532
10. Emanueli C., et al. Adenovirus-mediated human tissue kallikrein gene delivery induces angiogenesis in normoperfused skeletal muscle. Arterioscler. Thromb. Vasc. Biol. 20 (2000) 2379-2385
11. Emanueli C., et al. Local delivery of human tissue kallikrein gene accelerates spontaneous angiogenesis in mouse model of hindlimb ischemia. Circulation 103 (2001) 125-132
12. Emanueli C., et al. Nerve growth factor promotes angiogenesis and arteriogenesis in ischemic hindlimbs. Circulation 106 (2002) 2257-2262
13. Emanueli C., et al. Akt/protein kinase B and endothelial nitric oxide synthase mediate muscular neovascularization induced by tissue kallikrein gene transfer. Circulation 110 (2004) 1638-1644
14. Fahmy R.G., et al. Transcription factor Egr-1 supports FGF-dependent angiogenesis during neovascularization and tumor growth. Nat. Med. 9 (2003) 1026-1032
15. Grines C.L., et al. Angiogenic GENe Therapy (AGENT) trial in patients with stable angina pectoris. Circulation 105 (2002) 1291-1297
16. Hedman M., et al. Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia: phase II results of the Kuopio Angiogenesis Trial (KAT). Circulation 107 (2003) 2677-2683
17. Heeschen C., et al. CAPTURE (c7E3 Anti-Platelet Therapy in Unstable REfractory angina) Investigators. Prognostic significance of angiogenic growth factor serum levels in patients with acute coronary syndromes. Circulation 107 (2003) 524-530
18. Henry T.D., et al. The VIVA trial: Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis. Circulation 107 (2003) 1359-1365
19. Husain D., et al. Safety and efficacy of intravitreal injection of ranibizumab in combination with veterporfin PDT on experimental choroidal neovascularization in the monkey. Arch. Ophthalmol. 123 (2005) 509-515
20. Jain R.K., and Munn L.L. Leaky vessels? Call Ang1!. Nat. Med. 6 (2000) 131-132
21. Laflamme M.A., and Murry C.E. Regenerating the heart. Nat. Biotechnol. 23 (2005) 845-856
22. Landi F., et al. Topical treatment of pressure ulcers with nerve growth factor: a randomized clinical trial. Ann. Intern. Med. 139 (2003) 635-641
23. Losordo D.W., and Dimmeler S. Therapeutic angiogenesis and vasculogenesis for ischemic disease: Part I. Angiogenic cytokines. Circulation 109 (2004) 2487-2491
24. Losordo D.W., and Dimmeler S. Therapeutic angiogenesis and vasculogenesis for ischemic disease: Part II. Cell-based therapy. Circulation 109 (2004) 2692-2697
25. Lederman R.J., et al. Therapeutic Angiogenesis with Recombinant Fibroblast growth Factor-2 for Intermittent Claudication (the TRAFFIC study): a randomised trial. Lancet 359 (2002) 2053-2058
26. Makinen K., et al. Increased vascularity detected by digital subtraction angiography after VEGF gene transfer to human lower limb artery: a randomized, placebo-controlled, double-blinded phase II study. Molec. Ther. 6 (2002) 127-133
27. Porcu P., et al. Reversal of angiogenic growth factor upregulation by revascularization of lower limb ischemia. Circulation 105 (2002) 67-72
28. Porcu P., et al. Circulating tissue kallikrein levels correlate with severity of carotid atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 24 (2004) 1104-1110
29. Rajagopalan S., et al. Regional Angiogenesis with Vascular Endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation 108 (2003) 1933-1938
30. Rakic J.M., et al. Pegaptanib and age-related macular degeneration. N. Engl. J. Med. 352 (2005) 1720-1721
31. Richardson T.P., et al. Polymeric system for dual growth factor delivery. Nat. Biotechnol. 19 (2001) 1029-1034
32. Rissanen T.T., et al. Fibroblast growth factor 4 induces vascular permeability, angiogenesis and arteriogenesis in a rabbit hindlimb ischemia model. FASEB J. 17 (2003) 100-102
33. Sandri M., et al. Effects of exercise and ischemia on mobilization and functional activation of blood-derived progenitor cells in patients with ischemic syndromes results of three randomized studies. Circulation 111 (2005) 3391-3399
34. Schifitto G., et al. Long-term treatment with recombinant nerve growth factor HIV-associated sensory neuropathy. Neurology 57 (2001) 1313-1316
35. Simons M., et al. Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor: 2. Double-blind, randomized, controlled clinical trial. Circulation 105 (2002) 788-793
36. Slevin M., et al. Serial measurement of vascular endothelial growth factor and transforming growth factor-beta1 in serum of patients with acute ischemic stroke. Stroke 31 (2000) 1863-1870
37. Stewart D.J., et al. A phase 2, randomized, multicenter, 26-week study to assess the efficacy and safety of BIOBYPASS (AdGVVEGF121) delivered through minimally invasive surgery versus maximum medical treatment in patients with severe angina, advanced coronary artery stenosis, and no options for revascularization. Circulation 106 (2002) 23-26
38. Tuveri M., et al. NGF, a useful tool in the treatment of chronic vasculitic ulcers in rheumatoid arthritis. Lancet 356 (2000) 1739-1740
39. Vincent K.A., et al. Harnessing the response to tissue hypoxia: HIF-1 alpha and therapeutic angiogenesis. Trends Cardiovasc. Med. 12 (2002) 362-367
40. Visconti R.P., et al. Orchestration of angiogenesis and arteriovenous contribution by angiopoietins and vascular endothelial growth factor (VEGF). Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 8219-8224
41. Yla-Herttuala S., et al. Gene therapy for ischemic cardiovascular diseases: some lessons learned from the first clinical trials. Trends Cardiovasc. Med. 14 (2004) 295-300